Background: Most pathogenic mutations in the BRCA2 gene carry a high risk of hereditary breast and ovarian cancer (HBOC). However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer. The Icelandic population provides an opportunity for comprehensive characterization of the cancer risk profiles of K3326* and HBOC mutations because a single mutation, BRCA2 999del5, is responsible for almost all BRCA2-related HBOC in the population. Methods: Genotype information on 43 641 cancer patients and 370 971 control subjects from Iceland, the Netherlands, and the United States was used to assess the cancer risk profiles of K3326* and BRCA2 999del5. BRCA2 expression was assessed using RNAseq data from blood (n = 2233), as well as 52 tissues reported in the GTEx database. Results: The cancer risks associated with K3326* are fundamentally different from those associated with 999del5. We report for the first time an association between K3326* and small cell lung cancer (odds ratio [OR] = 2.06, 95% confidence interval [CI] = 1.35 to 3.16) and squamous cell carcinoma of the skin (OR = 1.69, 95% CI = 1.26 to 2.26). Individuals homozygous for K3326* reach old age and have children. Unlike BRCA2 999del5, the K3326* allele does not affect the level of BRCA2 transcripts, and the allele is expressed to the same extent as the wild-type allele. Conclusions: K3326* associates primarily with cancers that have strong environmental genotoxic risk factors. Expression of the K3326* allele suggests that a variant protein may be made that retains the DNA repair capabilities important to hormone-responsive tissues but may be less efficient in responding to genotoxic stress.
Background: Most pathogenic mutations in the BRCA2 gene carry a high risk of hereditary breast and ovarian cancer (HBOC). However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer. The Icelandic population provides an opportunity for comprehensive characterization of the cancer risk profiles of K3326* and HBOC mutations because a single mutation, BRCA2999del5, is responsible for almost all BRCA2-related HBOC in the population. Methods: Genotype information on 43 641 cancerpatients and 370 971 control subjects from Iceland, the Netherlands, and the United States was used to assess the cancer risk profiles of K3326* and BRCA2999del5. BRCA2 expression was assessed using RNAseq data from blood (n = 2233), as well as 52 tissues reported in the GTEx database. Results: The cancer risks associated with K3326* are fundamentally different from those associated with 999del5. We report for the first time an association between K3326* and small cell lung cancer (odds ratio [OR] = 2.06, 95% confidence interval [CI] = 1.35 to 3.16) and squamous cell carcinoma of the skin (OR = 1.69, 95% CI = 1.26 to 2.26). Individuals homozygous for K3326* reach old age and have children. Unlike BRCA2999del5, the K3326* allele does not affect the level of BRCA2 transcripts, and the allele is expressed to the same extent as the wild-type allele. Conclusions: K3326* associates primarily with cancers that have strong environmental genotoxic risk factors. Expression of the K3326* allele suggests that a variant protein may be made that retains the DNA repair capabilities important to hormone-responsive tissues but may be less efficient in responding to genotoxic stress.
Authors: M R Akbari; R Malekzadeh; D Nasrollahzadeh; D Amanian; F Islami; S Li; I Zandvakili; R Shakeri; M Sotoudeh; K Aghcheli; R Salahi; A Pourshams; S Semnani; P Boffetta; S M Dawsey; P Ghadirian; S A Narod Journal: Oncogene Date: 2007-08-27 Impact factor: 9.867
Authors: Brendan K Bulik-Sullivan; Po-Ru Loh; Hilary K Finucane; Stephan Ripke; Jian Yang; Nick Patterson; Mark J Daly; Alkes L Price; Benjamin M Neale Journal: Nat Genet Date: 2015-02-02 Impact factor: 38.330
Authors: Daniel F Gudbjartsson; Hannes Helgason; Sigurjon A Gudjonsson; Florian Zink; Asmundur Oddson; Arnaldur Gylfason; Soren Besenbacher; Gisli Magnusson; Bjarni V Halldorsson; Eirikur Hjartarson; Gunnar Th Sigurdsson; Simon N Stacey; Michael L Frigge; Hilma Holm; Jona Saemundsdottir; Hafdis Th Helgadottir; Hrefna Johannsdottir; Gunnlaugur Sigfusson; Gudmundur Thorgeirsson; Jon Th Sverrisson; Solveig Gretarsdottir; G Bragi Walters; Thorunn Rafnar; Bjarni Thjodleifsson; Einar S Bjornsson; Sigurdur Olafsson; Hildur Thorarinsdottir; Thora Steingrimsdottir; Thora S Gudmundsdottir; Asgeir Theodors; Jon G Jonasson; Asgeir Sigurdsson; Gyda Bjornsdottir; Jon J Jonsson; Olafur Thorarensen; Petur Ludvigsson; Hakon Gudbjartsson; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; David O Arnar; Olafur Th Magnusson; Augustine Kong; Gisli Masson; Unnur Thorsteinsdottir; Agnar Helgason; Patrick Sulem; Kari Stefansson Journal: Nat Genet Date: 2015-03-25 Impact factor: 38.330
Authors: S Thorlacius; G Olafsdottir; L Tryggvadottir; S Neuhausen; J G Jonasson; S V Tavtigian; H Tulinius; H M Ogmundsdottir; J E Eyfjörd Journal: Nat Genet Date: 1996-05 Impact factor: 38.330
Authors: Igor V Kutyavin; Dave Milesi; Yevgeniy Belousov; Mikhail Podyminogin; Alexei Vorobiev; Vladimir Gorn; Eugeny A Lukhtanov; Nicolaas M J Vermeulen; Walt Mahoney Journal: Nucleic Acids Res Date: 2006-09-29 Impact factor: 16.971
Authors: Jian Sang; Tongwu Zhang; Jung Kim; Mengying Li; Angela C Pesatori; Dario Consonni; Lei Song; Jia Liu; Wei Zhao; Phuc H Hoang; Dave S Campbell; James Feng; Monica E D'Arcy; Naoise Synnott; Yingxi Chen; Zeni Wu; Bin Zhu; Xiaohong R Yang; Kevin M Brown; Jiyeon Choi; Jianxin Shi; Maria Teresa Landi Journal: Hum Mol Genet Date: 2022-10-10 Impact factor: 5.121
Authors: Thorunn Rafnar; Bjarni Gunnarsson; Olafur A Stefansson; Patrick Sulem; Andres Ingason; Michael L Frigge; Lilja Stefansdottir; Jon K Sigurdsson; Vinicius Tragante; Valgerdur Steinthorsdottir; Unnur Styrkarsdottir; Simon N Stacey; Julius Gudmundsson; Gudny A Arnadottir; Asmundur Oddsson; Florian Zink; Gisli Halldorsson; Gardar Sveinbjornsson; Ragnar P Kristjansson; Olafur B Davidsson; Anna Salvarsdottir; Asgeir Thoroddsen; Elisabet A Helgadottir; Katrin Kristjansdottir; Orri Ingthorsson; Valur Gudmundsson; Reynir T Geirsson; Ragnheidur Arnadottir; Daniel F Gudbjartsson; Gisli Masson; Folkert W Asselbergs; Jon G Jonasson; Karl Olafsson; Unnur Thorsteinsdottir; Bjarni V Halldorsson; Gudmar Thorleifsson; Kari Stefansson Journal: Nat Commun Date: 2018-09-07 Impact factor: 14.919
Authors: Upekha E Liyanage; Matthew H Law; Xikun Han; Jiyuan An; Jue-Sheng Ong; Puya Gharahkhani; Scott Gordon; Rachel E Neale; Catherine M Olsen; Stuart MacGregor; David C Whiteman Journal: Hum Mol Genet Date: 2019-09-15 Impact factor: 6.150
Authors: Yuan Lin; Roxana Daneshjou; Kavita Y Sarin; Andrey Ziyatdinov; Gudmar Thorleifsson; Adam Rubin; Luba M Pardo; Wenting Wu; Paul A Khavari; Andre Uitterlinden; Tamar Nijsten; Amanda E Toland; Jon H Olafsson; Bardur Sigurgeirsson; Kristin Thorisdottir; Eric Jorgensen; Alice S Whittemore; Peter Kraft; Simon N Stacey; Kari Stefansson; Maryam M Asgari; Jiali Han Journal: Nat Commun Date: 2020-02-10 Impact factor: 14.919
Authors: Olafur A Stefansson; Holmfridur Hilmarsdottir; Kristrun Olafsdottir; Laufey Tryggvadottir; Asgerdur Sverrisdottir; Oskar T Johannsson; Jon G Jonasson; Jorunn E Eyfjord; Stefan Sigurdsson Journal: JNCI Cancer Spectr Date: 2019-12-11